GeoVax Labs Announces Results of 2026 Annual Meeting and Approval of Warrant Exercise Proposals

GeoVax Labs, Inc. held its annual meeting of stockholders on June 17, 2026, where several key proposals were approved. Stockholders elected a seven-member slate of directors to serve until the next annual meeting, including Randal D. Chase, David A. Dodd, and Nicole Lemerond. Significant focus was placed on equity matters, with stockholders approving the issuance of common stock upon the exercise of warrants from three separate transactions in 2026: a February private placement (up to 865,804 shares), a March warrant exercise inducement (up to 1,269,316 shares), and a May warrant exercise inducement (up to 1,702,986 shares). These approvals were required pursuant to Nasdaq listing rules. Additionally, stockholders ratified Wipfli LLP as the independent auditor for the fiscal year ending December 31, 2026, and approved executive compensation on an advisory basis. Stockholders also recommended that future advisory votes on executive compensation occur every three years. Out of 2,892,570 outstanding shares, 1,288,684 shares were represented at the meeting.